THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, December 06, 2021
A medical technology company that pioneers biotech subtractive immunotherapies, Terumo Blood and Cell Technologies and Immunicom has signed a co-commercialization agreement. Additionally, as per the agreement, Terumo will be the sole exclusive distributor in Germany, Italy, France, and Spain, with potential for future geographic expansion.
FREMONT, CA: A medical technology company that pioneers biotech subtractive immunotherapies, Terumo Blood and Cell Technologies and Immunicom has signed a co-commercialization agreement. The firms are collaborating in the US with the aim to improve cancer therapy that selectively eliminates immune inhibitors from a patient’s bloodstream. This therapy facilitates the immune system to more effectively attack tumors. Immunicom’s technology is based on a subtractive approach that is meant to limit any adverse effects which other immunotherapy pharmaceuticals result in as foreign compounds are introduced into the body causing negative effects. The combination of Terumo’s Spectra Optia Apheresis System with Immunicom’s CE marked immuno-oncology LW-02 Column will be implemented in the application to treat patients with advanced refractory triple-negative breast cancer. In order to meaningfully address this advanced cancer that frequently evades standard treatments and represents a significant global unmet medical need, this collaboration is an vital milestone in the advancement of Immunicom’s subtractive therapy.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Additionally, as per the agreement, Terumo will be the sole exclusive distributor in Germany, Italy, France, and Spain, with potential for future geographic expansion. From the beginning of 2013, Terumo Blood and Cell Technologies have supported Immunicom says Amir Jafri, founder, and chief executive of Immunicom. On the international commercialization of our flagship immunotherapy offering, the company strategically partnered with Immunicom as they had a strong global presence and shared commitment to advancing standards of care through innovation making them the natural choice. This alliance shows strong long-term growth potential as LW-02 Column is the only first many platform-based subtractive therapies under development at Immunicom. Furthermore, Antoinette Gawain, president, and chief executive, Terumo Blood and Cell Technologies, which is a subsidiary of Terumo Corporation (TSE: 4543) said that if we imagine a scenario where someone is battling with late-stage breast cancer can mitigate the effects of chemotherapy, and spend their final days actively engaging with those they love, shaping their final memories, to offer this to the patients they are combining their technology with Immunicom’s.
More in News